Company intelligence / Profile preview
Shanghai Angecon Biotechnology
Shanghai, Shanghai, Chinaangecon.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 1
01
Overview
Shanghai Angecon Biotechnology is a private Chinese biotech company focused on developing therapeutics for central nervous system disorders, including brain injuries, stroke, Alzheimer's disease, and spinal cord injury. Its lead assets are in the preclinical or pending stage with no reported clinical results to date.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shanghai Angecon Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Angecon Biotechnology.